FDA Grants Breakthrough Device Designation to Virtuoso Surgical Robotic System
Virtuoso Surgical has received FDA Breakthrough Device Designation for its Virtuoso Surgical Robotic System, designed for the removal of bladder lesions via en bloc excision.
The designation recognises the system’s potential to improve early diagnosis and treatment of bladder cancer.
The Virtuoso system features a patented, surgeon-controlled platform with needle-sized robotic arms that enhance precision and dexterity during minimally invasive procedures performed with rigid endoscopes.
It addresses the need for higher-quality specimens and more accurate staging in bladder lesion removal, improving patient outcomes compared with standard transurethral approaches.
Virtuoso Surgical brings together expertise in surgical robotics, urology, engineering, and artificial intelligence. The system enables en bloc resection, preserving the integrity of tissue specimens and providing more accurate cancer staging.
The system has already been used successfully in a series of bladder lesion excisions, demonstrating its ability to perform en bloc resections efficiently and safely.
By improving specimen quality and surgical accuracy, the technology could reduce local recurrence and provide more reliable pathological results for guiding treatment decisions.
The FDA Breakthrough Devices Program supports the development and expedited review of medical devices offering significant improvements in diagnosing or treating life-threatening or severely debilitating conditions.
Devices granted this designation, like the Virtuoso system, benefit from faster regulatory interactions, prioritised feedback, and accelerated assessment pathways to reach patients more quickly once safety and effectiveness are confirmed.